Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.
Launched by SHENGJING HOSPITAL · Jun 12, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new and safer way to diagnose liver damage in patients with chronic liver disease using advanced Magnetic Resonance Imaging (MRI) techniques. These techniques aim to measure how stiff the liver is, how much fat it contains, and whether there’s inflammation or scarring. The goal is to create a method that can provide accurate results without needing to perform liver biopsies, which can be risky and only sample a small part of the liver.
To participate in this trial, individuals must be between the ages of 18 and 75 and have chronic liver disease, such as viral hepatitis or alcoholic liver disease. Participants will undergo MRI scans to gather information about their liver health. It’s important to note that some people may not be eligible, particularly those with certain medical conditions, implants, or who are pregnant. This trial is currently recruiting participants, and those involved can expect a non-invasive approach to better understand their liver condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..)
- • 2. Age range of 18 to 75 years old
- • 3. Accept systematic antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy
- Exclusion Criteria:
- • 1. Age less than 18 years
- • 2. Unable or unwilling to give informed consent
- • 3. Contra-indications to MRI
- • 4. Electrical implants such as cardiac pacemakers or perfusion pumps
- • 5. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
- • 6. Ferromagnetic objects such as jewelry or metal clips in clothing
- • 7. Pregnant subjects
- • 8. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions
About Shengjing Hospital
Shengjing Hospital, affiliated with the China Medical University, is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on multidisciplinary collaboration, the hospital leverages its state-of-the-art facilities and a team of experienced healthcare professionals to conduct comprehensive studies aimed at improving patient outcomes. Shengjing Hospital is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all clinical trials are designed to enhance medical knowledge and provide safe, effective treatment options for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenyang, Liaoning, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported